{"product_id":"alpha-1-antichymotrypsin-antibody-aact-serpina3-bha17129189","title":"Alpha-1-Antichymotrypsin Antibody \/ AACT \/ SERPINA3","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eAlpha-1-Antichymotrypsin Antibody \/ AACT \/ SERPINA3 is an antibody targeting \u003cstrong\u003eAACT\u003c\/strong\u003e, raised in \u003cstrong\u003eRabbit\u003c\/strong\u003e for protein detection and localization studies where these specifications are required.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e AACT.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eAntibody identity:\u003c\/strong\u003e Polyclonal (rabbit origin); Rabbit IgG.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eConjugate\/label:\u003c\/strong\u003e Unconjugated (affects detection chemistry and multiplex compatibility).\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eListed applications:\u003c\/strong\u003e WB, FACS, Direct ELISA (refer to on-page specifications for application-specific guidance).\u003c\/li\u003e \u003c\/ul\u003e  \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eAlpha 1-antichymotrypsin, also called serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 or GIG24 is an alpha globulin glycoprotein that is a member of the serpin superfamily. In humans, it is encoded by the SERPINA3 gene. This gene is mapped to 14q32.13. The protein encoded by this gene is a plasma protease inhibitor and member of the serine protease inhibitor class. Polymorphisms in this protein appear to be tissue specific and influence protease targeting. Variations in this protein's sequence have been implicated in Alzheimer's disease, and deficiency of this protein has been associated with liver disease. Mutations have been identified in patients with Parkinson disease and chronic obstructive pulmonary disease.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eComparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).\u003c\/li\u003e \u003cli\u003eSubcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.\u003c\/li\u003e \u003cli\u003eIntegration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eWestern blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003cli\u003eFlow cytometry: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003cli\u003eELISA: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eInterpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands\/signals accordingly.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eEpitope context:\u003c\/strong\u003e binding can depend on protein conformation and sample processing; region information in the title\/immunogen can help anticipate what may be detected.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eSpecies differences:\u003c\/strong\u003e predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e include negative controls (no-primary\/isotype), and where possible genetic controls (KO\/KD) or independent antibodies to strengthen conclusions.\u003c\/li\u003e \u003c\/ul\u003e \u003c!-- Sources (internal): - UniProtKB entry P01011 — UniProt — https:\/\/www.uniprot.org\/uniprotkb\/P01011 - Gene search: AACT — NCBI Gene — https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=AACT - Ensembl search: AACT — Ensembl — https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=AACT - PubMed search: AACT antibody — PubMed — https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=AACT+antibody - Reactome search: AACT — Reactome — https:\/\/reactome.org\/content\/query?q=AACT --\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53046448226669,"sku":"RQ7626","price":449.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_4d8812e4-80af-43a9-99d3-5b8c91b450db.jpg?v=1772000689","url":"https:\/\/www.ebiohippo.com\/products\/alpha-1-antichymotrypsin-antibody-aact-serpina3-bha17129189","provider":"BioHippo","version":"1.0","type":"link"}